openPR Logo
Press release

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market 2016 - 2024 : Partek, Inc, GnuBIO, and Caris Life Sciences

08-31-2018 02:19 PM CET | Health & Medicine

Press release from: TMR Research

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Snapshot

With the advent of new technology, the potential that next generation sequencing (NGS) application holds in genetic counseling, disease management and treatment, and risk assessment is remarkable. From a clinical perspective, the technology can be applied to prenatal diagnosis, molecular diagnosis of genetic and infectious diseases, medical genetics and pharmacogenomics, carrier detection, cancer molecular diagnosis, and prognosis.

In terms of technology, targeted sequencing and re-sequencing is a major contributor to the clinical oncology next generation sequencing market in the U.S. This technological segment will gain traction by enabling even higher throughput at reduced price per sample. Due to a decrease in the complexity of implementation, the use of whole genome sequencing (WGS) technology to make comparisons between tumor tissue and normal tissue is expected to witness a steep rise during the forecast period. In addition, researchers are of the opinion that through WSG everyone will be able to develop a personalized treatment plan. The segment is expected to grow further with the introduction of new tools such as NextSeq and MiniSeq platforms, which are likely to enhance the implement ability for a broad spectrum of research labs with varying sequencing needs.

Based on end user, the U.S. market for clinical oncology next generation sequencing is segmented into pharmaceutical and biotech entities, clinical research, academic research institutes, and hospitals and clinics. Owing to growing awareness regarding the benefits associated with the implementation of second-generation sequencing in academic and university-based research projects, academic institutes will hold a strong presence in the clinical oncology next generation sequencing market.

There are numerous players operating in the U.S. market. To hold their dominant position, many are banking on capitalizing data analysis requirements and need for more robust sequencing platforms through mergers and funding deals between major and minor players. A case in point would be Partek collaborating with Kennedy Krieger Institute. Together they have developed a commercial software for analyzing chromosomal abnormalities in diseases such as autism spectrum disorder, bipolar disorder, and schizophrenia.

Request Sample Copy of the Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=47

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Overview

With continued enhancement of new sequencing technology, next-generation sequencing (NGS) is being increasingly used in cancer genomics research. Also known as massively parallel sequencing, these days NGS is being leveraged in clinical oncology to provide improved tailored therapy for cancer. Next generation sequencing finds application in detecting rare forms of cancer mutations, uncovering familial cancer mutation carriers, and in providing molecular rationale for the exact targeted therapy. Hence, it is widely considered as a disruptive technology in the area of cancer treatment.

There have been many noteworthy achievements in the field of cancer genetics in the past couple of years on account of cutting-edge technologies and tanking costs of next-generation sequencing (NGS). The report by TMR Research offers key insights into the U.S. clinical oncology Next Generation Sequencing (NGS) market. It studies the degree of research and development in next generation sequencing for clinical oncology and furnishes crucial market figures from 2017 to 2025.

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Trends and Opportunities

Next generation sequencing has a number of advantages over traditional sequencing. First is its ability to completely sequence every kind of mutations for a large number of genes in one test cost-effectively. However, challenges exist in leveraging NGS, especially with respect to the need for simpler assays, more flexible throughput, reduced turnaround time, and most importantly in analyzing and interpreting the data. Overall, continued efforts to apply NGS in clinical oncology will take us one step closer to personalized medicine.

Request TOC of the Report @

https://www.tmrresearch.com/sample/sample?flag=T&rep_id=47

In the U.S., the clinical oncology next generation sequencing market has been buoyed by the astute initiatives of the government in the field of research and development in oncology. For example, loans and grants have been liberally disbursed by the U.S. government and various funding bodies to bring down the gap between genomic sequence analysis platforms development and their use in oncology research. In the near future, the substantial increase in spending related to cancer in the U.S. is slated to further drive up the demand for second generation sequencing platforms for diagnostic monitoring and theranostics applications.

A major challenge to the next generation sequencing is the time taken to uncover insights from the copious amount of data generated after the genome is sequenced. While this benefits the cancer patients as its aids in accurately studying many genes simultaneously that may be relevant to the patient’s tumor by using only a small amount of tissue at a reasonable cost, it also accords innumerable opportunities to commercial service providers to come up with proper solutions in much less time.

Companies Mentioned in Report

To present an in-depth assessment of the competition prevailing in the U.S. market for clinical oncology next generation sequencing, the report profiles companies such as Roche, llumina Inc., Pacific Bioscience, Agilent Technologies, GATC Biotech Ag, Macrogen Inc., Oxford Nanopore Technologies Ltd, Foundation Medicine, Life technologies Corp, Exosome Diagnostics, CLC Bio, Paradigm, Perkin Elmer, Inc, Inc, Partek, Inc, GnuBIO, and Caris Life Sciences.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/us-clinical-oncology-next-generation-sequencing-market

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Clinical Oncology Next Generation Sequencing (NGS) Market 2016 - 2024 : Partek, Inc, GnuBIO, and Caris Life Sciences here

News-ID: 1214769 • Views: 151

More Releases from TMR Research

Global Private LTE Market Analysis by Market Key Player, Product Application & G …
Global Private LTE Market: Overview The global private LTE market likely to registers significant growth during the course of forecast period from the period between 2018 till 2028. Moreover, this network provides the better alternatives of the public networks on account of high operational efficiency, low cost deployment and improved business application in terms of security. The private LTE market also provide more capacity and coverage and has facility to modify
Crude Sulfate Turpentine Market 2025 Harting S.A., Arizona Chemical Company LLC, …
Global Crude Sulfate Turpentine Market: Snapshot The global market for crude sulfate turpentine is growing at a robust pace and is likely to witness significant growth in the coming years. The increasing use of crude sulfate turpentine in diverse applications is expected to encourage the growth of the global market in the coming years. In addition, the rising demand for high-value products for personal care, especially in developing economies is likely
Wood Vinegar Market 2017 Analysis, Growth, Vendors, Shares, Drivers, Challenges …
Global Wood Vinegar Market: Snapshot Pyroligneous acid, commonly known as wood vinegar, is created from wood and plant materials, using a process known as destructive distillation. The core ingredients of wood vinegar include acetone, methanol, and acetic acid, and was historically used to produce acetic acid on large scales. Currently, the scope of use of wood vinegar stretches across a large number of application segments. One of the more common uses
Meat Processing Equipment Market 2025 | Key Technology Inc., JBT Corporation, Ma …
Global Meat Processing Equipment Market: Snapshot Changing food preferences, lifestyles, tastes, and habits of the global population have bolstered the growth of the market for meat processing equipment. Developing economies such as China and India have been exhibiting enormous demand for meat over the last few decades. Industrialization, growing urbanization, Western influence on the food habits of Eastern consumers, and the growing disposable incomes of people have offset the growth of

All 5 Releases


More Releases for NGS

NGS Data Analysis Market to Undertake Strapping Growth During 2026
With continuous developments in cloud computing and data integration solutions, bottlenecks in data handling are being effectively addressed, which includes high throughput sequence data’s sizeable volume analysis. Introduction of NGS solutions coupled with rising clinical diagnosis requirement for personalized treatment of several ailments and genomic research, have created demand for precise and fasts sequencing and algorithms interpretation tools that can analyze data faster. This Fact.MR report analyzes the expansion of
NGS Data Analysis Market to Observe Strong Development by 2026
With continuous developments in cloud computing and data integration solutions, bottlenecks in data handling are being effectively addressed, which includes high throughput sequence data’s sizeable volume analysis. Introduction of NGS solutions coupled with rising clinical diagnosis requirement for personalized treatment of several ailments and genomic research, have created demand for precise and fasts sequencing and algorithms interpretation tools that can analyze data faster. Report overview @ https://www.xploremr.com/report/679/ngs-data-analysis-market This Fact.MR report analyzes
Next-generation Sequencing (NGS) Market Unbeaten over 2025
Next-generation Sequencing (NGS) Market: Snapshot Next Generation Sequencing (NGS) is utilized to execute different applications, for instance, biomarker revelation, oncology thinks about, customized solution, rural and creature research, and others. NGS has streamlined nucleotide investigation and has broadly supplanted customary instruments of genomics, particularly microarray effectively. The interest for NGS has expanded altogether inferable from surge in NGS applications and ascend in mechanical progressions in NGS. What's more, the development in
Next Generation Sequencing (NGS) Data Analysis Market Trepidation In 2025
Next Generation Sequencing (NGS) Data Analysis Market: Snapshot NGS is the term which is used to describe a number of different modern sequencing technologies and is also known as high throughput sequencing. Researchers are allowed to examine the biological systems, deeply due to exceptional throughput, scalability of systems, and speed by the next generation sequencing (NGS). In present times, a greater level of understanding is demanded due to the complexities involved
Global Next Generation Sequencing (NGS) Market Is driven by Increased in adoptio …
The Global Next-Generation Sequencing (NGS) Market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global Next-Generation Sequencing (NGS) Market for
Next Generation Sequencing (NGS) at a CAGR of 23.59%
The Asia-Pacific NGS market which was worth $ 567.7 million in 2016 is poised to reach $1,636.7 million by 2021 at a CAGR of 23.59%. Asia presents significant opportunities for the investors/venture capitalists as the developed markets are saturated. The presence of noteworthy developments by China and Japan for integration of new technologies and the development of healthcare is majorly driving the Asia Pacific Market. Sample Report Request: https://www.reportsandmarkets.com/sample-request/1214607-12/2016 R&D and